z-logo
Premium
Discovery of novel selective hypotensive vasopressin peptides that exhibit little or no functional interactions with known oxytocin/vasopressin receptors
Author(s) -
Chan W Y,
Wo N C,
Stoev S,
Cheng L L,
Manning M
Publication year - 1998
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0702114
Subject(s) - vasopressin , oxytocin , vasopressin receptor , neuropeptide , oxytocin receptor , receptor , neuroscience , biology , chemistry , pharmacology , endocrinology , medicine , antagonist
1 Arginine‐vasopressin (VP) has both vasoconstricting and vasodilating action. We report here the discovery of four novel selective hypotensive VP analogues: d(CH 2 ) 5 [D‐Tyr(Et) 2 ,Arg 3 ,Val 4 ]AVP; d(CH 2 ) 5 [D‐Tyr(Et) 2 ,Lys 3 ,Val 4 ]AVP and their iodinatable Tyr‐NH 2 9 analogues. 2 Bioassays in rats for activities characteristic of neurohypophysial peptides showed that the four VP peptides possessed little or no V 1a , V 2 or oxytocin (OT) receptor agonistic or antagonistic activities. 3 In anaesthetized rats, these peptides (0.05–0.10 mg kg −1 i.v.) elicited a marked fall in arterial blood pressure. 4 Blockade of cholinoceptors, adrenoceptors and bradykinin B 2 receptors, and inhibition of prostaglandin synthesis had little effect on their vasodepressor action. 5 Classical V 1a , V 2 and OT receptor antagonists did not block the vasodepressor response. 6 L ‐NAME, 0.2 mg kg −1  min −1 , markedly suppressed the hypotensive response to ACh but not the vasodepressor response to the hypotensive VP peptides. However, the duration of the vasodepressor response was shortened. Very high doses of L ‐NAME attenuated both the vasodepressor response and the duration of action. 7 These findings indicate that the vasodepressor action of these VP peptides is independent of the peripheral autonomic, bradykinin and PG systems and is not mediated by the known classical OT/VP receptors. NO does not appear to have an important role in their vasodepressor action. 8 The discovery of these novel VP peptides could lead to the development of new tools for the investigation of the complex cardiovascular actions of VP and the introduction of a new class of hypotensive agents. The two iodinatable hypotensive VP peptides could be radiolabelled as potential markers for the localization of the receptor system involved.British Journal of Pharmacology (1998) 125 , 803–811; doi: 10.1038/sj.bjp.0702114

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom